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FIRST CLINICAL CASE REPORTFirst detection of Aspergillus fumigatus azole-resistant strain due to Cyp51A
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es (E. Mellado)A 76-year-old man with increased basal dyspnoea, pleuritic-
type chest pain and fever was admitted to the Hospital Gre-
gorio Marañón, Madrid, in May 2014. The patient had been
diagnosed with chronic obstructive pulmonary disease in 1997,
and since then his baseline situation had worsened; he now
manifested chronic respiratory failure treated with high-dose
corticotherapy. In the present admission, Aspergillus fumigatus
was cultured from sputum; however, galactomannan detection,
calcoﬂuor stain and PCR assay in bronchoalveolar lavage ﬂuid
were negative. The patient had no obvious clinical signs of
invasive aspergillosis, and this isolation was considered a colo-
nization following the revised EORTC/MSG criteria [1].
Strain identiﬁcation (TP90812) was conﬁrmed as A. fumigatus
by PCR ampliﬁcation and sequencing. The full coding sequences
of the gene encoding the azole target (cyp51A gene including itsNew Microbes and New Infections © 2015 The Authors. Published by El
This is an open access artipromoter) was PCR ampliﬁed and sequenced [2], showing the
newly described azole resistance mechanism, consisting of a
46 bp tandem repeat in the promoter region of cyp51A along
with two punctual mutations in the coding sequence of the
cyp51A gene (a433t and a936g), leading to substitutions of
tyrosine to phenylalanine at codon 121 and a threonine to
alanine at codon 289 (TR46/Y121F/T289A) [3].
Antifungal susceptibility test was performed using the broth
microdilution method described by the European Committee
on Antimicrobial Susceptibility Testing [4]. The A. fumigatus
strain azole minimum inhibitory concentrations were itraco-
nazole 2.0, voriconazole (VRC) >8.0 and posaconazole 0.5 and
would be considered resistant to VRC and with intermediate
minimum inhibitory concentration values to itraconazole and
posaconazole [5].
The number of clinical isolates of azole-resistant A. fumigatus
is gradually increasing. Triazole resistance can evolve during
therapy, but resistant isolates are also being detected in azole-
naive patients [6]. We report the ﬁrst isolation of a VRC-
resistant A. fumigatus strain TR46/Y121F/T289A in an azole-
naive patient in Spain.
To date, A. fumigatus azole resistance is mostly associated to
modiﬁcations of the target site (encoded by cyp51A) and its
overexpression. The main azole resistance mechanism is
mediated by a tandem repeat of 34 bases in the promoter ofNew Microbe and New Infect 2015; 6: 33–34
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TABLE 1. Reports of azole-resistant strains carrying TR46/
Y121F/T289A mutation in cyp51A gene, by country
Continent First reported
No. of
strains Year Origin Study
Europe Germany 1 2012 Clinical [8]
The Netherlands 21 2009–11 Clinical [3]
14 2013 Environment
Belgium 1 2012 Clinical [7]
Denmark 1 2014 Clinical [9]
Spain 1 2014 Clinical This work
Africa Tanzania 4 2014 Environment [10]
Asia India 6 2012–13 Environment [10]
34 New Microbes and New Infections, Volume 6 Number C, July 2015 NMNIcyp51A gene and a substitution in position 98 (TR34/L98H) [3].
This mechanism is spreading across Europe, and it has been
related to azole fungicide use in agriculture [6]. A new resis-
tance mechanism responsible for VRC resistance, TR46/Y121F/
T289A in the cyp51A gene, was ﬁrst detected in 2009 in a
Dutch patient [4] and has recently been reported in other
countries [7–10] (Table 1).
To our knowledge, this is the ﬁrst case report of this speciﬁc
mutation in an A. fumigatus clinical isolate in Spain. Although
there has yet been not recovery of a TR46/Y121F/T289A azole-
resistant A. fumigatus strains from the environment in Spain, its
isolation from an azole-naive patient is an interesting ﬁnding,
suggesting that an effective analysis of clinical and environmental
sources must be done to detect azole resistance in A. fumigatus.
The emergence and spread of this new azole resistance
mechanism in A. fumigatus is of major concern because it
conferred high resistance to VRC and is associated with
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